Asker Healthcare Group AB
Asker Healthcare Group AB provides medical supplies, devices, and equipment, and related solutions that support patient care. It offers protective products, infusion products, and dressings; measuring instruments for diabetes and blood pressure; and endoscopy equipment, incubators, and ventilators, as well as pharmaceuticals. The company also provides, supplies, and distributes fittings and equip… Read more
Asker Healthcare Group AB (I88) - Net Assets
Latest net assets as of June 2025: €6.42 Billion EUR
Based on the latest financial reports, Asker Healthcare Group AB (I88) has net assets worth €6.42 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€15.21 Billion) and total liabilities (€8.78 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.42 Billion |
| % of Total Assets | 42.24% |
| Annual Growth Rate | 12.01% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.1 |
Asker Healthcare Group AB - Net Assets Trend (2022–2024)
This chart illustrates how Asker Healthcare Group AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Asker Healthcare Group AB (2022–2024)
The table below shows the annual net assets of Asker Healthcare Group AB from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.50 Billion | +15.16% |
| 2023-12-31 | €3.04 Billion | +8.96% |
| 2022-12-31 | €2.79 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Asker Healthcare Group AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 47.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.65 Billion | 47.62% |
| Other Components | €1.82 Billion | 52.38% |
| Total Equity | €3.47 Billion | 100.00% |
Asker Healthcare Group AB Competitors by Market Cap
The table below lists competitors of Asker Healthcare Group AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Jufei Optoelectronics
SHE:300303
|
$1.35 Billion |
|
Shenzhen Clou Electronics Co Ltd
SHE:002121
|
$1.35 Billion |
|
Dime Community Bancshares Inc
NASDAQ:DCOM
|
$1.35 Billion |
|
Qi An Xin Technology Group Inc
SHG:688561
|
$1.35 Billion |
|
Hebei Sinopack Electronic Technolog
SHE:003031
|
$1.35 Billion |
|
Lien Hwa Industrial Corp
TW:1229
|
$1.35 Billion |
|
Hamilton Insurance Group, Ltd.
NYSE:HG
|
$1.35 Billion |
|
MINISO GROUP A DL-0001
F:MIF0
|
$1.35 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Asker Healthcare Group AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,023,000,000 to 3,469,000,000, a change of 446,000,000 (14.8%).
- Net income of 360,000,000 contributed positively to equity growth.
- Other factors increased equity by 86,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €360.00 Million | +10.38% |
| Other Changes | €86.00 Million | +2.48% |
| Total Change | €- | 14.75% |
Book Value vs Market Value Analysis
This analysis compares Asker Healthcare Group AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.81x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €7.21 | €5.84 | x |
| 2023-12-31 | €7.89 | €5.84 | x |
| 2024-12-31 | €9.06 | €5.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Asker Healthcare Group AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.38%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.40%
- • Asset Turnover: 1.15x
- • Equity Multiplier: 3.78x
- Recent ROE (10.38%) is below the historical average (10.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 15.56% | 3.67% | 1.15x | 3.70x | €153.70 Million |
| 2023 | 6.72% | 1.51% | 1.19x | 3.75x | €-99.30 Million |
| 2024 | 10.38% | 2.40% | 1.15x | 3.78x | €13.10 Million |
Industry Comparison
This section compares Asker Healthcare Group AB's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,489,429,632,124
- Average return on equity (ROE) among peers: -106.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Asker Healthcare Group AB (I88) | €6.42 Billion | 15.56% | 1.37x | $1.35 Billion |
| KIMIA FARMA -B- (HQP) | $5.89 Trillion | 5.13% | 1.93x | $78.59 Million |
| Paragon Care Limited (PXS) | $18.21 Million | 5.96% | 0.48x | $52.33 Million |
| TELES Informationstechnologien AG (TLIK) | $379.23K | -446.97% | 3.69x | $801.14K |
| Sinopharm Group Co. Ltd (X2S) | $68.28 Billion | 8.55% | 2.45x | $3.26 Billion |